Compare LC & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LC | MLTX |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2008 | 2020 |
| Metric | LC | MLTX |
|---|---|---|
| Price | $18.12 | $17.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $22.64 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 1.7M | 750.1K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $314,702,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.35 | N/A |
| P/E Ratio | $39.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.42 | $5.95 |
| 52 Week High | $21.67 | $62.75 |
| Indicator | LC | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.67 | 49.59 |
| Support Level | $16.35 | $15.89 |
| Resistance Level | $18.89 | $19.24 |
| Average True Range (ATR) | 0.79 | 0.82 |
| MACD | 0.07 | -0.09 |
| Stochastic Oscillator | 80.95 | 33.08 |
LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.